BioSpace News Archive

Medalogix and Amedisys announced an expanded partnership with the implementation of Medalogix Pulse for Home Health patients.

Heranova Lifesciences Holding Ltd. announced the successful completion of a USD 13.5 million seed and seed+ financing to develop and offer integrated Women’s Health solutions worldwide.

SeaStar Medical Holding Corporation announces enrollment of 12 subjects in the NEUTRALIZE-AKI pivotal clinical trial evaluating the safety and efficacy of its patented, first-in-class, cell-directed Selective Cytopheretic Device extracorporeal therapy in critically ill adults with acute kidney injury requiring continuous kidney replacement therapy.

NeuroBo Pharmaceuticals, Inc. announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration.

Sight Sciences, Inc. announced by five Medicare Administrative Contractors to withdraw their final local coverage determinations for Micro-Invasive Glaucoma Surgery that were scheduled to take effect on January 29, 2024.

Neurolief, a global leader in medical devices delivering groundbreaking neurotechnology innovations for the treatment of Neurological and Neuropsychiatric disorders, is pleased to announce a strategic equity investment from Sawai Group Holdings Co., Ltd.

Cytek Biosciences, Inc. announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

HR Pharmaceuticals, Inc. announced that they have entered into an Exclusive Commercial Agreement with Poiesis Medical LLC, under which HRP will license Poiesis’s Dual Balloon Catheter.

Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation System* as a first-line treatment for persistent atrial fibrillation, the only trial to study the use of PFA as frontline therapy in patients with this form of AF.

Titan Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock, which will be effective following the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation.